Acadian Asset Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Acadian Asset Management’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,180	Closed	-$11K	–	1746
2023 Q2	$11K	Sell	2,180 -204	-9%	-$4.28K	﹤0.01%	1676
2023 Q1	$70K	Buy	+2,384	New	+$89.1K	﹤0.01%	1462
2020 Q1	–	Sell	-1	Closed	-$5K	–	1857
2019 Q4	$5K	Sell	1 -2	-67%	-$3.88K	﹤0.01%	1776
2019 Q3	$4K	Hold	3	–	–	﹤0.01%	1820
2019 Q2	$4K	Buy	3 +2	+200%	+$2.95K	﹤0.01%	1698
2019 Q1	$1K	Sell	1 -17	-94%	-$41.3K	﹤0.01%	1930
2018 Q4	$46K	Buy	18 +4	+29%	+$9.23K	﹤0.01%	1440
2018 Q3	$24K	Buy	+14	New	+$37.6K	﹤0.01%	1490
2018 Q2	–	Sell	-3	Closed	-$6K	–	1778
2018 Q1	$6K	Buy	+3	New	+$13K	﹤0.01%	1607

Other funds holding KPRX

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Acadian Asset Management's KPRX Position: Q3 2023 in Review

Acadian Asset Management sold out of Kiora Pharmaceuticals (KPRX) in Q3 2023, closing a stake of 2,180 shares — an estimated $11K sold.

Acadian Asset Management first reported a position in KPRX in Q1 2018 and held it in 9 quarters. The position peaked at $70K in Q1 2023. 13 funds tracked by Wall St. Rank hold KPRX as of Q3 2023.

Acadian Asset Management reported no remaining Kiora Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Acadian Asset Management sold 2,180 Kiora Pharmaceuticals shares in Q3 2023, an estimated $11K.
Acadian Asset Management first reported a position in Kiora Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Acadian Asset Management's Kiora Pharmaceuticals position peaked at $70K in Q1 2023.
13 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.